Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VNDA
  • CUSIP: 92165910
  • Web: www.vandapharmaceuticals.com
Capitalization:
  • Market Cap: $715.06 million
  • Outstanding Shares: 44,552,000
Average Prices:
  • 50 Day Moving Avg: $15.67
  • 200 Day Moving Avg: $14.56
  • 52 Week Range: $10.98 - $18.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -59.26
  • P/E Growth: -1.48
Sales & Book Value:
  • Annual Revenue: $150.17 million
  • Price / Sales: 4.75
  • Book Value: $2.88 per share
  • Price / Book: 5.56
Profitability:
  • EBIDTA: ($4,590,000.00)
  • Net Margins: -8.85%
  • Return on Equity: -10.42%
  • Return on Assets: -6.44%
Debt:
  • Current Ratio: 2.31%
  • Quick Ratio: 2.30%
Misc:
  • Average Volume: 476,852 shs.
  • Beta: 1.51
  • Short Ratio: 4.15
 
Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.04. The company had revenue of $37.42 million for the quarter, compared to the consensus estimate of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. View Vanda Pharmaceuticals' Earnings History.

When will Vanda Pharmaceuticals make its next earnings announcement?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Vanda Pharmaceuticals.

Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued 1 year price objectives for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $24.00. On average, they anticipate Vanda Pharmaceuticals' stock price to reach $21.75 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:

  • H. Thomas Watkins, Independent Chairman of the Board
  • Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director
  • James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
  • Richard L Gulino, Senior Vice President, General Counsel, Secretary
  • Gian Piero Reverberi, Senior Vice President, Acting Chief Commercial Officer and European General Manager
  • Kenneth M. Bate, Director
  • Michael F. Cola, Independent Director
  • Richard W. Dugan, Independent Director
  • Vincent J. Milano, Independent Director

Who owns Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.21%), Bank of Montreal Can (0.18%), Cheyne Capital Management UK LLP (0.17%), Strs Ohio (0.11%), Shell Asset Management Co. (0.07%) and Capital One National Association (0.04%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Boston Advisors LLC, Strs Ohio, Gagnon Securities LLC and Capital One National Association. Company insiders that have sold Vanda Pharmaceuticals stock in the last year include James E Flynn and Richard L Gulino. View Insider Buying and Selling for Vanda Pharmaceuticals.

Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?

Vanda Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Russell Investments Group Ltd.. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy Vanda Pharmaceuticals stock?

Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $16.00.


MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)
Community Ranking:  3.9 out of 5 (  )
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.75 (35.94% upside)

Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/27/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$23.00LowView Rating Details
5/26/2017HC WainwrightInitiated CoverageBuy -> Buy$18.00LowView Rating Details
5/25/2017Jefferies Group LLCReiterated RatingBuy$21.00MediumView Rating Details
4/12/2017CIBCReiterated RatingOutperform -> Outperform$21.00LowView Rating Details
4/12/2017Oppenheimer Holdings, Inc.Initiated CoverageOutperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 -> $22.00N/AView Rating Details
3/14/2016Canaccord GenuityReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.28)N/AView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)
2017 EPS Consensus Estimate: ($0.66)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.18)($0.15)($0.17)
Q2 20172($0.27)($0.20)($0.24)
Q3 20172($0.19)($0.14)($0.17)
Q4 20172($0.14)($0.05)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 92.51%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.00View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.44View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.80View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS
www.americanbankingnews.com - July 27 at 11:17 AM
seekingalpha.com logoVanda Pharmaceuticals: An Early Stage Bioscience Consideration - Seeking Alpha
seekingalpha.com - July 27 at 9:15 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:58 AM
finance.yahoo.com logoVanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
finance.yahoo.com - July 22 at 10:21 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 21 at 10:56 AM
streetinsider.com logoVanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia - StreetInsider.com
www.streetinsider.com - July 21 at 8:28 AM
prnewswire.com logoVanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:09 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:14 PM
finance.yahoo.com logoVanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 17 at 10:47 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - July 17 at 7:06 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
finance.yahoo.com - July 14 at 4:59 PM
americanbankingnews.com logo$40.37 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - July 5 at 11:47 AM
americanbankingnews.com logoZacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.23 EPS
www.americanbankingnews.com - July 3 at 10:14 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - June 27 at 9:14 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 10:15 AM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At JMP Securities Life Sciences Conference 2017 - Slideshow
seekingalpha.com - June 22 at 7:37 PM
seekingalpha.com logoVanda: Several Catalysts Coming Up - Seeking Alpha
seekingalpha.com - June 22 at 2:35 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : June 21, 2017
finance.yahoo.com - June 22 at 2:35 PM
finance.yahoo.com logoVanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
finance.yahoo.com - June 22 at 2:35 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 14 at 2:18 PM
seekingalpha.com logoVanda Pharmaceuticals (VNDA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 2:03 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - June 7 at 8:42 AM
prnewswire.com logoVanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences - PR Newswire (press release)
www.prnewswire.com - June 7 at 8:17 AM
americanbankingnews.com logo-$0.23 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - June 7 at 8:04 AM
finance.yahoo.com logoVanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences
finance.yahoo.com - June 6 at 1:50 AM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Corcept ... - PR Newswire (press release)
www.prnewswire.com - May 30 at 3:26 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 11:04 AM
americanbankingnews.com logoVanda Pharmaceuticals' (VNDA) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - May 26 at 12:58 PM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017
finance.yahoo.com - May 22 at 7:36 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 2:50 PM
americanbankingnews.com logo$40.3 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - May 13 at 9:00 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 11 at 10:44 AM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017
finance.yahoo.com - May 9 at 9:44 AM
americanbankingnews.com logoAnalysts Set Vanda Pharmaceuticals Inc. (VNDA) Price Target at $21.71
www.americanbankingnews.com - May 8 at 11:33 PM
bizjournals.com logoVanda Pharmaceuticals expands into cystic fibrosis, blood cancer - Washington Business Journal
www.bizjournals.com - May 6 at 3:30 PM
finance.yahoo.com logoETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 6 at 1:17 AM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 11:52 AM
americanbankingnews.com logoAnalysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM
finance.yahoo.com logoVanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 5 at 3:23 AM
finance.yahoo.com logoVanda Pharmaceuticals expands into cystic fibrosis, blood cancer
finance.yahoo.com - May 5 at 3:23 AM
americanbankingnews.com logoFY2020 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - May 4 at 8:04 PM
americanbankingnews.com logoFY2020 Earnings Forecast for Vanda Pharmaceuticals Inc. (VNDA) Issued By Jefferies Group
www.americanbankingnews.com - May 4 at 8:04 PM
americanbankingnews.com logoSomewhat Positive Press Coverage Somewhat Likely to Affect Vanda Pharmaceuticals (VNDA) Stock Price
www.americanbankingnews.com - May 4 at 4:46 PM
americanbankingnews.com logoVanda Pharmaceuticals Inc. (VNDA) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 4:58 PM
seekingalpha.com logoVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:53 AM
finance.yahoo.com logoEdited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 9:53 AM
finance.yahoo.com logoInvestor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 6:37 PM
finance.yahoo.com logoVanda Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 6:37 PM

Social

Chart

Vanda Pharmaceuticals (VNDA) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff